Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Hind Al Azzawi"'
Autor:
Jayastu Senapati, Emmanuel Huante Almanza, Tapan M. Kadia, Guillermo Montalban-Bravo, Stefan Faderl, Koji Sasaki, Nicholas Short, Naval Daver, Courtney D. DiNardo, Lucia Masarova, Alessandra Ferrajoli, Elias Jabbour, Gautam Borthakur, Hind Al Azzawi, Marina Konopleva, Guillermo Garcia-Manero, Michael Andreeff, Hagop Kantarjian, Farhad Ravandi, Yesid Alvarado
Publikováno v:
Blood. 140:9050-9053
Autor:
Hayley Balkin, Marina Konopleva, Prithviraj Bose, Tapan M. Kadia, William G. Wierda, Philip A. Thompson, Farhad Ravandi, Rebecca Garris, Joseph D. Khoury, Nitin Jain, Naval Daver, Stefan Faderl, Mary A. Kelly, Yesid Alvarado, Abhishek Maiti, Susan O'Brien, Hagop M. Kantarjian, Naveen Pemmaraju, Elias Jabbour, Steven M. Kornblau, Hind Al Azzawi, Jan A. Burger, Guillermo Garcia-Manero, Nicholas J. Short, Alessandra Ferrajoli, Gautam Borthakur
Publikováno v:
Blood. 136:36-39
Background: Intensive chemotherapy has improved complete remission (CR) rates in T-ALL/LBL. However, long-term overall survival (OS) continues to be suboptimal at about 50%. Nelarabine (NEL) is active in relapsed/refractory T-ALL. PEG-asparaginase (P
Autor:
Guillermo Montalban-Bravo, Sherry Pierce, Gautham Borthakur, Koji Sasaki, Courtney D. DiNardo, Naval Daver, Lucia Masarova, Naveen Pemmaraju, Yesid Alvarado, Alessandra Ferrajoli, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Michael Andreeff, Tapan M. Kadia, Stefan Faderl, Elias Jabbour, Jorge M. Ramos Perez, Hind Al Azzawi, Marina Konopleva
Publikováno v:
Blood. 136:32-34
INTRODUCTION: The outcome of patients (pts) with relapsed or refractory AML (R/R AML) or MDS after failing hypomethylating agents (HMA) and/or BCL-2 inhibitor combinations is poor. CPX-351 is a liposomal formulation of cytarabine and daunorubicin, ap
Autor:
Daniel Rivera, Tapan M. Kadia, Guillermo Montalban-Bravo, Stefan Faderl, Koji Sasaki, Nicholas J. Short, Naval Daver, Courtney D. DiNardo, Lucia Masarova, Alessandra Ferrajoli, Elias J. Jabbour, Gautham Borthakur, Hind Al Azzawi, Marina Konopleva, Guillermo Garcia-Manero, Michael Andreeff, Hagop Kantarjian, Farhad Ravandi, Yesid Alvarado
Publikováno v:
Blood. 138:2323-2323
INTRODUCTION: The outcome of patients (pts) with R/R AML or MDS after failing HMA and/or BCL-2 inhibitor combinations is poor. CPX-351 (Vyxeos™) is a dual liposomal formulation of cytarabine and daunorubicin, at a fixed synergistic 5:1 molar ratio,
Autor:
William G. Wierda, Nitin Jain, Jan A. Burger, Marina Konopleva, Alessandra Ferrajoli, Yasmin Abaza, Prithviraj Bose, Gautam Borthakur, Stefan Faderl, Deborah A. Thomas, Hind Al Azzawi, Farhad Ravandi, Naval Daver, Jorge E. Cortes, Mary A. Kelly, Partow Kebriaei, Philip A. Thompson, Hagop M. Kantarjian, Yesid Alvarado, Guillermo Garcia-Manero, Rebecca Garris, Tapan M. Kadia, Naveen Pemmaraju, Bouthaina S. Dabaja, Susan O'Brien, Preetesh Jain, Elias Jabbour, Steven M. Kornblau, Joseph D. Khoury
Publikováno v:
American Journal of Hematology. 93:91-99
Nelarabine, a water soluble prodrug of 9-β-D-arabinofuranosylguanine (ara-G), is a T-cell specific purine nucleoside analogue. Given its activity in relapsed and refractory T acute lymphoblastic leukemia (T-ALL) and T lymphoblastic lymphoma (T-LBL),
Autor:
Jorge M. Ramos Perez, Tapan M. Kadia, Guillermo Montalban-Bravo, Christopher B. Benton, Stefan Faderl, Koji Sasaki, Kiran Naqvi, Jorge E. Cortes, Naval G. Daver, Courtney D. DiNardo, Elias Jabbour, Gautam M. Borthakur, Hind Al Azzawi, Naveen Pemmaraju, Marina Y Konopleva, Sherry A. Pierce, Nitin Jain, Maro Ohanian, Guillermo Garcia-Manero, Michael Andreeff, Hagop M. Kantarjian, Farhad Ravandi, Yesid Alvarado
Publikováno v:
Blood. 134:2642-2642
INTRODUCTION: The outcome of patients (pts) with relapsed or refractory AML (R/R AML) or MDS after failing hypomethylating agents (HMA) is poor. CPX-351 is a liposomal formulation of cytarabine and daunorubicin, approved by the US Food and Drug Admin
Autor:
Judy H. Chiao, Daniella Zheleva, Hind Al Azzawi, David Blake, Tapan M. Kadia, Gautam Borthakur
Publikováno v:
Blood. 134:1379-1379
Cyclin dependent kinases (CDKs) are critical for cell cycle regulation and transcriptional elongation. Dysregulated CDKs have been linked to the cancer hallmarks of uncontrolled proliferation and increased survival. CYC065 is a potent and orally‐av